The Diagnostic Electrocardiograph (ECG) Market in the Middle East & Africa has been calculated at USD 435.27 million in 2022 and estimated to grow at a CAGR of 6.03%, reaching USD 583.32 million by 2027.
A significant factor driving the diagnostic electrocardiograph market in the Middle East and Africa is the continuous rise in the incidence of cardiovascular and lifestyle-related diseases, such as ischemic heart disease, stroke, peripheral artery disease, and hypertensive heart disease, all of which contribute to an increase in heart failure-related mortality.
Cardiovascular disease is the leading cause of death in the Middle East and Africa. An aging population, improved health care infrastructure, increased government funding, technological breakthroughs in the field of medical sciences, and many firms engaging in R&D are all predicted to fuel market expansion.
Electrocardiograph devices have grown in popularity due to their accuracy and precision in detecting chronic illnesses like heart disease. Non-invasive diagnostic equipment is used to assess the heart's electrical activity and discover disorders linked to the heart's electrical activity, which is anticipated to favor the diagnostic ECG market in the MEA region.
The market is further expected to rise due to the rising prevalence of cardiovascular illnesses and lifestyle-related disorders such as ischemic heart disease, hypertensive heart disease, stroke, and peripheral artery disease. In addition, the diagnostic electrocardiograph (ECG) market in the Middle East and Africa is predicted to grow because of an aging population and improved healthcare infrastructure.
However, the growth of the diagnostic electrocardiograph (ECG) market in the Middle East and Africa is likely to be impeded by a lack of public awareness about the use of electrographs in the diagnosis of cardiovascular problems as a scarcity of experienced staff to operate electrograph equipment. In addition, high pricing associated with diagnostic electrocardiograph equipment, unpredictable economic situations, and the necessity for scheduled maintenance checks are projected to stifle market expansion in the Middle East and Africa throughout the forecast period. Furthermore, unfavorable government reimbursement laws, the development of healthcare infrastructure, and rising public and private sector R&D spending are all impediments to market growth.
This research report on the MEA Diagnostic ECG Market has been segmented and sub-segmented into the following categories:
By Lead Type:
By End Users:
Geographically, the Middle East and Africa accounted for a moderate portion of the global diagnostic electrocardiograph market in 2020. An increase in the incidence and prevalence of cardiovascular and lifestyle-related diseases, as well as a well-established healthcare infrastructure, technological advancements, and a surge in research and development, as well as increased funding from the government and large corporations, have all contributed to the region's steadily growing market share.
Minimally invasive techniques are becoming more popular. Furthermore, during the projection period, the region's diagnostic electrocardiograph market will be propelled to new heights by a growing geriatric population and rising per-capita income.
Diagnostic electrocardiograph market analysis in UAE and Kuwait, including healthcare capital expenditure growth, installed base of various types of products for the healthcare analytical testing services market, impact changes in healthcare regulatory scenarios, and their impact on the diagnostic electrocardiograph industry, employing lifeline curves.
Chronic heart disease is becoming more common throughout the Middle East and Africa due to changes in lifestyle and dietary patterns, necessitating proper testing procedures such as diagnostic electrocardiographs.
KEY MARKET PLAYERS:
Companies leading the MEA Diagnostic Electrocardiograph Market profiled in this report are BPL Ltd, Cardiac Science Corp, Fukuda Denshi Co., Ltd, GE Healthcare, Medtronic, Inc., Philips Healthcare, Spacelabs Healthcare, Inc., Mortara Instrument, Inc., Midmark Corp, Mindray Medical International Ltd, Nihon Kohden Corp, Scottcare Corp, Schiller Ag, Welch Allyn Inc., and Cardionet.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org